| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | 4-hydroxybutyric acid | FAERS: 2 | US FAERS | |
| 2 | sibutramine | FAERS: 2 | US FAERS | |
| 3 | tofacitinib | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 4 | Albendazole | FAERS: 1 | US FAERS | |
| 5 | Atovaquone | FAERS: 1 | US FAERS | |
| 6 | Ortho Evra | FAERS: 1 | US FAERS | |
| 7 | PCI 32765 | FAERS: 1 | US FAERS | |
| 8 | Ruxolitinib phosphate | FAERS: 1 | US FAERS | |
| 9 | Sorafenib | FAERS: 1 | US FAERS | |
| 10 | Teriparatide | FAERS: 1 | US FAERS | |
| 11 | Zoledronic Acid | FAERS: 1 | US FAERS | |
| 12 | atovaquone, proguanil drug combination | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 13 | etonogestrel | FAERS: 1 | US FAERS |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120326
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.